BYSIBeyondSpring Inc.
- GlobeNewswire
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on First-Line Immune Checkpoint Inhibitor (ICI) Therapy AACR 2026 Preclinical ...
- GlobeNewswire
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
Dr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully ...
- GlobeNewswire
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitorsDurable survival benefit: 12-month OS ...
- GlobeNewswire
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
FLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other ...
- GlobeNewswire
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue ...
- GlobeNewswire
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy Plinabulin's GEF-H1 Agonist Mechanism ...
- GlobeNewswire
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and ...
- GlobeNewswire
BeyondSpring Files 2025 Annual Report on Form 10-K
FLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and ...
- GlobeNewswire
BeyondSpring Reports 2025 Year-End Financial Results
Plinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care docetaxel in EGFR ...
- GlobeNewswire
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the ...
- GlobeNewswire
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path
Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT ...
- GlobeNewswire
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a ...
- GlobeNewswire
BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update
Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
8-K Form - Current report, items 1.01, 8.01, and 9.01 - BeyondSpring Inc. (0001677940) (Filer)
Current report, items 1.01, 8.01, and 9.01 ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
8-K Form - Current report, item 5.07 - BeyondSpring Inc. (0001677940) (Filer)
Current report, item 5.07 ...
- Earnings Call Transcripts
BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)
BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript) ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - BeyondSpring Inc. (0001677940) (Issuer)
Statement of changes in beneficial ownership of securities ...